摘要：SummaryAdvances in the treatment of Ewing's sarcoma (EWS) are desperately needed, particularly in the case of metastatic disease. A deeper understanding of collateral sensitivity, where the evolution of therapeutic resistance to one drug aligns with sensitivity to another drug, may improve our ability to effectively target this disease. For the first time in a solid tumor, we produced a temporal collateral sensitivity map that demonstrates the evolution of collateral sensitivity and resistance in EWS. We found that the evolution of collateral resistance was predictable with some drugs but had significant variation in response to other drugs. Using this map of temporal collateral sensitivity in EWS, we can see that the path toward collateral sensitivity is not always repeatable, nor is there always a clear trajectory toward resistance or sensitivity. Identifying transcriptomic changes that accompany these states of transient collateral sensitivity could improve treatment planning for patients with EWS.Graphical AbstractDisplay OmittedHighlights•Ewing's sarcoma cell lines were evolved to become resistant to standard chemotherapy•A temporal collateral sensitivity map shows response to alternative drugs over time•Collateral drug response is repeatable in some instances and stochastic in others•Differential gene expression elucidates potential biomarkers of drug responseBiological Sciences; Evolutionary Biology; Cancer Systems Biology; Cancer
